Alirocumab is a fully human monoclonal antibody to PCSK9. The ODYSSEY MONO study was the first alirocumab Phase III study to test a previously unused dose of 75 mg subcutaneously every 2 weeks in ...

Praluent (alirocumab) and Repatha (evolocumab) are in the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor drug class. The active ingredient in Praluent is alirocumab, and the ...

Exempting life-saving drugs from customs duty is a significant policy aimed at improving access Drugs like Alirocumab and Evolocumab are used to treat high cholesterol By lowering the import duty ...